Current status and future prospects for the treatment of antiphospholipid syndrome

Expert Review of Clinical Immunology

Volumn 12, Issue 9, 2016, Pages 927-935

  Al Marzooqi, Ahlam ^a   Leone, Alessia ^b   Al Saleh, Jamal ^a   Khamashta, Munther ^a,c  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

anticardiolipin; Lupus anticoagulant; miscarriages; stroke; thrombosis; treatment

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL PRODUCT; PHOSPHOLIPID ANTIBODY; RAPAMYCIN; AUTOANTIBODY; HYDROXYCHLOROQUINE; RITUXIMAB;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ASYMPTOMATIC DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; EXPERIMENTAL THERAPY; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREGNANCY DISORDER; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC); TERMINAL DISEASE; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ANIMAL; BLOOD; COMPLICATION; DRUG EFFECTS; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; PROCEDURES;

ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; RITUXIMAB; THROMBOSIS;

EID: 84965045437     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1178573     Document Type: Review

References (79)

1. V.Pengo, A.Ruffatti, C.Legnani, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–242.
2. V.Pengo, A.Ruffatti, C.Legnani, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile:a multicenter prospective study. Blood. 2011;118:4714–4718.
3. M.H.Rosove, P.M.Brewer Antiphospholipid thrombosis:clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–308.
4. R.H.Derksen, P.G.de Groot, L.Kater, et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993;52:689–692.
5. Y.Shoenfeld, M.Blank, R.Cervera, et al. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006;65(1):2–6.
6. L.Andreoli, C.B.Chighizola, A.Banzato, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke myocardial infarction, and deep vein thrombosis:a critical review of the literature. Arthritis Care Res. 2013;65:1869–1873.
7. R.T.Urbanus, B.Siegerink, M.Roest, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study:a case-control study. Lancet Neurol. 2009;8:998–1005.
8. J.P.Buyon, M.Y.Kim, M.M.Guerra, et al. Predictors of pregnancy outcomes in patients with lupus:a cohort study. Ann Intern Med. 2015;163:153–163.•• Lupus anticoagulant is the main predictor of adverse pregnancy outcome in aPL-positive patients.
9. P.L.Meroni, C.B.Chighizola, F.Rovelli, et al. Antiphospholipid syndrome in 2014:more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16:209.• Review of potential new markers for the diagnosis of APS.
10. K.Otomo, T.Atsumi, O.Amengual, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–512.
11. K.Oku, O.Amengual, T.Atsumi. Antiphospholipid scoring:significance in diagnosis and prognosis. Lupus. 2014;23:1269–1272.
12. S.Sciascia, G.Sanna, V.Murru, et al. GAPSS:the global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52:1397–1403.
13. H.Meijide, S.Sciascia, G.Sanna, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies:a systematic review. Autoimmun Rev. 2013;12:421–425.
14. D.G.Wahl, H.Bounameaux, P.de Moerloose, et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies:do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042–2048.
15. D.Erkan, M.J.Harrison, R.Levy, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome:a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–2391.
16. M.J.Cuadrado, M.L.Bertolaccini, P.T.Seed, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis:a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014;53:275–284.
17. M.Fangtham, M.Petri. 2013 update:Hopkins lupus cohort. Curr Rheumatol Rep. 2013;15:360.
18. M.H.Edwards, S.Pierangeli, X.Liu, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380–4384.
19. R.Kaiser, C.M.Cleveland, L.A.Criswell. Risk and protective factors for thrombosis in systemic lupus erythematosus:results from a large, multiethnic cohort. Ann Rheum Dis. 2009;68:238–241.
20. G.Ruiz-Irastorza, M.Ramos-Casals, P.Brito-Zeron, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus:a systematic review. Ann Rheum Dis. 2010;69:20–28.
21. D.Erkan, C.L.Aguiar, D.Andrade, et al. 14th international congress on antiphospholipid antibodies:task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–696.
22. S.Sciascia, B.J.Hunt, E.Talavera-Garcia, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214:273.e1–273.e8.
23. G.Ruiz-Irastorza, M.J.Cuadrado, I.Ruiz-Arruza, et al. Evidence based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody positive patients:report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011;20:206–218.
24. M.A.Crowther, J.S.Ginsberg, J.Julian, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–1138.
25. G.Finazzi, R.Marchioli, V.Brancaccio, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–853.
26. G.Ruiz-Irastorza, M.A.Khamashta, B.J.Hunt, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome:analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med. 2002;162:1164–1169.
27. M.A.Khamashta, M.J.Cuadrado, F.Mujic, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–997.
28. H.Cohen, B.J.Hunt, M.Efythymiou, et al. Rivaroxaban in antiphospholipid syndrome (RAPS):a prospective, randomized controlled non-inferiority phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. N Engl J Med. Forthcoming 2016
29. N.Noel, F.Dutasta, N.Costedoat-Chalumeau, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14:680–685.
30. S.R.Levine, R.L.Brey, B.C.Tilley, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–584.
31. H.Okuma, Y.Kitagawa, T.Yasuda, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2010;7:15–18.
32. G.Ruiz-Irastorza, B.J.Hunt, M.A.Khamashta. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–1495.
33. J.A.Vargas-Hitos, O.Ateka-Barrutia, S.Sangle, et al. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–1654.
34. S.Sciascia, O.Giachino, D.Roccatello. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012;30:409–413.
35. S.Tenti, S.Cheleschi, G.M.Guidelli, et al. Intravenous immunoglobulins and antiphospholipid syndrome:how, when and why? A review of the literature. Autoimmun Rev. 2016;15:226–235.
36. B.Artim-Esen, R.Diz-Küçükkaya, M.İnanç. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17:14.
37. T.Scoble, S.Wijetilleka, M.A.Khamashta. Management of refractory anti-phospholipid syndrome. Autoimmun Rev. 2011;10:669–673.
38. J.Bakshi, R.Stevens. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus. 2013;22:865–867.
39. D.Erkan, J.Vega, G.Ramon, et al. A pilot open-label phase II trial of rituximab for non criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–471.
40. S.Bucciarelli, G.Espinosa, R.Cervera, et al. Mortality in the catastrophic antiphospholipid syndrome:causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–2576.
41. G.J.Pons-Estel, G.E.Salerni, R.M.Serrano, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases:report of 31 cases and review of the literature. Autoimmun Rev. 2011;10:679–684.
42. H.Berman, I.Rodríguez-Pintó, R.Cervera, et al. Rituximab use in the catastrophic antiphospholipid syndrome:descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–1090.
43. B.E.Lonze, A.A.Zachary, C.M.Magro, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459–465.
44. B.E.Lonze, A.L.Singer, R.A.Montgomery. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744–1745.
45. R.S.Rai, L.Regan, K.Clifford, et al. Antiphospholipid antibodies and beta2-glycoprotein I in 500 women with recurrent miscarriage:result of a comprehensive screening approach. Hum Reprod. 1995;10:2001–2005.
46. R.S.Rai, K.Clifford, H.Cohen, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10:3301–3304.
47. G.R.de Jesus, N.Agmon-Levin, C.A.Andrade, et al. 14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795–813.
48. M.Empson, M.Lassere, J.Craig, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;18:CD002859.
49. P.D.Ziakas, M.Pavlou, M.Voulgarelis. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss:a systematic review and meta-analysis. Obstet Gynecol. 2010;115:1256–1262.
50. F.Carmona, J.Font, J.Balasch, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies:a multivariate analysis. Am J Reprod Immunol. 2001;46:274–279.
51. O.Ateka-Barrutia, C.Nelson-Piercy. Connective tissue disease in pregnancy. Clin Med (Lond). 2013;13:580–584.
52. C.R.Albert, W.J.Schlesinger, C.A.Viall, et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol. 2014;71:154–164.
53. K.Bramham, M.Thomas, C.Nelson-Piercy, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody–related pregnancy loss. Blood. 2011;117:6948–6951.
54. L.Statkute, A.Traynor, Y.Oyama, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106:2700–2709.
55. N.Hashimoto, T.Iwasaki, M.Sekiguchi, et al. Autologous hematopoietic stemcell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis. Bone Marrow Transplantat. 2004;33:863–866.
56. T.M.Owaidah, K.Maghrabi, M.A.Elkarouri, et al. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT:case report and review of literature. Bone Marrow Transplant. 2011;46:597–600.
57. G.Canaud, F.Bienaimé, F.Tabarin, et al., Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:303–312.•• A new pathogenic mechanism in aPL-related vasculopathy.
58. J.de la Mata, M.A.Gomez-Sanchez, M.Aranzana, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 1994;37:1528–1533.
59. A.Akkerman, W.Huang, X.Wang, et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity. 2004;37:445–451.
60. S.Khattri, G.Zandman-Goddard, E.Peeva. B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun Rev. 2012;11:717–722.
61. A.Vilas-Boas, S.A.Morais, D.A.Isenberg. Belimumab in systemic lupus erythematosus. RMD Open. 2015;1(1):e000011.
62. W.Stohl, F.Hiepe, K.M.Latinis, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328–2337.
63. H.Zhou. Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. Acta Pharmacol Sin. 2004;25:1366–1371.
64. H.Zhou, A.S.Wolberg, R.A.Roubey. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004;104:2353–2358.
65. S.S.Pierangeli, D.Erkan. Antiphospholipid syndrome treatment beyond anticoagulation:arewe there yet? Lupus. 2010;19:475–485.
66. C.Comarmond, P.Cacoub. Antiphospholipid syndrome:from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013;12:752–757.
67. M.V.Ostertag, X.Liu, V.Henderson, et al. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus. 2006;15:358–365.
68. Y.M.de la Torre, F.Pregnolato, F.D’Amelio, et al. Antiphospholipid induced murine fetal loss:novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid binding. J Autoimmun. 2012;38:J209–J215.
69. C.Pericleous, P.Ruiz-Limón, Z.Romay-Penabad, et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford). 2015;54:722–727.
70. T.McDonnell, C.Pericleous, E.Laurine, et al. Development of a high yield expression and purification system for domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnol. 2015;15:104.
71. C.Agostinis, P.Durigutto, D.Sblattero, et al. A non-complement fixing antibody to β2 glycoprotein i as a novel therapy for antiphospholipid syndrome. Blood. 2014;123:3478–3487.
72. A.Kolyada, C.J.Lee, A.De Biasio, et al. A novel dimeric inhibitor targeting Beta2gpi in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. PLoS One. 2010;5:e15345.
73. A.Kolyada, A.Porter, N.Beglova. Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood. 2014;123:1090–1097.
74. R.Jasuja, F.H.Passam, D.R.Kennedy, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Investig. 2012;122:2104–2113.
75. S.Schulman, E.Svenungsson, S.Granqvist. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. Am J Med. 1998;104:332–338.
76. C.Lopez-Pedrera, P.Ruiz-Limon, M.A.Aguirre, et al. Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep. 2012;14:87–94.• Good review of the potential role of statins in prevention of APS thrombosis.
77. D.Erkan, R.Willis, V.L.Murthy, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73:1176–1180.
78. P.M.Ridker, E.Danielson, F.A.Fonseca, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
79. B.Giannkopoulos, S.A.Krilis, The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–1044.•• An excellent review of pathogenic mechanisms in APS.